Clifford Chance's Moscow office has advised Pfizer on its agreement to provide finance and technology to Russian pharmaceutical company NovaMedica for the construction of a new production facility in Russia, with the medicines licensed and manufactured under the agreement to be sold by Pfizer and NovaMedica in Russia and the CIS.
According to Clifford Chance, "the collaboration is driven by the Russian government's 'localization' policy for the pharmaceutical sector, through which medicines manufactured in Russia are preferred in tenders for medicines for the public health service.
NovaMedica's current shareholders are the Russian government-backed technology fund RUSNANO and U.S. healthcare venture capital fund Domain Associates. According to Clifford Chance, "the collaboration was recently voted Deal of the Year by industry peers at an annual Russian pharmaceutical industry awards ceremony (the Platinum Ounce awards)."
The Clifford Chance team in Moscow was led by Partner Torsten Syrbe and Senior Associate Andrew Robinson. Pfizer's in-house legal team was led by Karen Saah in New York, with support from Lilia Danilova in Moscow. The cross-practice team in Clifford Chance's Moscow office also included Senior Associates Ekaterina Sharapova, Ekaterina Matveychuk, Michael Anderson, Maria Chivragova, Sardaana Nogovitsyna, Dmitry Malukevich, Vitaly Koloskov, Olga Mizikova and Kamilla Shikhametova, Associates Ilya Stekunov and Ani Tangyan, and Trainee Anna Semenova.